Siddiqui, B. A., Gheeya, J. S., Goswamy, R., Bathala, T. K., Surasi, D. S., Gao, J., . . . Tannir, N. (2021). Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer.
Stile di citazione ChicagoSiddiqui, Bilal A., et al. "Durable Responses in Patients With Genitourinary Cancers Following Immune Checkpoint Therapy Rechallenge After Moderate-to-severe Immune-related Adverse Events." J Immunother Cancer 2021.
Citazione MLASiddiqui, Bilal A., et al. "Durable Responses in Patients With Genitourinary Cancers Following Immune Checkpoint Therapy Rechallenge After Moderate-to-severe Immune-related Adverse Events." J Immunother Cancer 2021.